Show simple item record

dc.contributor.authorBowyer, S
dc.contributor.authorPrithviraj, P
dc.contributor.authorLorigan, Paul C
dc.contributor.authorLarkin, J
dc.contributor.authorMcArthur, G
dc.contributor.authorAtkinson, V
dc.contributor.authorMillward, M
dc.contributor.authorKhou, M
dc.contributor.authorDiem, S
dc.contributor.authorRamanujam, S
dc.contributor.authorKong, B
dc.contributor.authorLiniker, E
dc.contributor.authorGuminski, A
dc.contributor.authorParente, P
dc.contributor.authorAndrews, M C
dc.contributor.authorParakh, S
dc.contributor.authorCebon, J
dc.contributor.authorLong, G
dc.contributor.authorCarlino, M
dc.contributor.authorKlein, O
dc.date.accessioned2016-05-25T15:29:09Zen
dc.date.available2016-05-25T15:29:09Zen
dc.date.issued2016-05-10en
dc.identifier.citationEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. 2016, 114 (10):1084-9 Br J Canceren
dc.identifier.issn1532-1827en
dc.identifier.pmid27124339en
dc.identifier.doi10.1038/bjc.2016.107en
dc.identifier.urihttp://hdl.handle.net/10541/610720en
dc.description.abstractRecent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy.
dc.language.isoenen
dc.rightsArchived with thanks to British journal of canceren
dc.titleEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.en
dc.typeArticleen
dc.contributor.departmentRockingham General Hospital, Cooloongup, Western Australia, Australiaen
dc.identifier.journalBritish Journal of Canceren
html.description.abstractRecent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy.


This item appears in the following Collection(s)

Show simple item record